BMLBMLKF 69 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BMLKF with a GF Score™ of 69/100 and a GF Value™ of $26.78. The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, BML ranks better than 68.63% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BML's Free Cash Flow for the
three
months ended in Mar. 2026 was $0.0 Mil. BML's Revenue for the
three
months ended in Mar. 2026 was $225.5 Mil. Therefore, BML's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for BML's FCF Margin % or its related term are showing as below:
BMLKF'
s FCF Margin % Range Over the Past 10 Years
Min: -4.7 Med: 7.02 Max: 20.7
Current: 6.73
During the past 13 years, the highest FCF Margin % of BML was 20.70%. The lowest was -4.70%. And the median was 7.02%.
BMLKF's FCF Margin % is ranked better than 68.63% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs BMLKF: 6.73
BML FCF Margin % Related Terms
BML FCF Margin % Historical Data
* Premium members only.
The historical data trend for BML's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BML's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BML FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BML's FCF Margin % distribution charts can be found below:
* The bar in red indicates where BML's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BML (BMLKF) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BML and its competitors. According to the industry distribution chart, BML ranks #64 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 31.4%.
Is BML's FCF Margin % too high?
BML's current FCF Margin % is 0.00%. Based on the distribution chart, BML ranks #64 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BML has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does BML's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BML ranks #64 out of 204 companies for FCF Margin %. This puts BML in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BML and its competitors. BML's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BML stock overvalued right now?
BML (BMLKF) has a current FCF Margin % of 0.00%. The stock's GF Value™ is $26.78, compared to a current price of $25.21 — trading 5.9% below its estimated fair value. The current FCF Margin % is 0.00%. BML's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BML (BMLKF), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BML (BMLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BML stock appears to be undervalued.
The current stock price of $25.21 is trading 5.9% below its estimated GF Value™ of $26.78.
Key valuation signals for BMLKF:
FCF Margin %: 0.00%
GF Value™: $26.78 vs. price of $25.21 (5.9% below fair value)
No single metric tells the full story. See the BMLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.
69GF Score
Get the complete analysis for BMLKF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMLKF has been successfully added to your 
